Global Platelet Rich Plasma (PRP) Market to Reach $1.6 Billion by 2030
The global market for Platelet Rich Plasma (PRP) estimated at US$815.6 Million in the year 2022, is projected to reach a revised size of US$1.6 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2022-2030. Pure Platelet Rich Plasma, one of the segments analyzed in the report, is projected to record 8.5% CAGR and reach US$833.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Leukocyte Rich Platelet Rich Plasma segment is readjusted to a revised 10.5% CAGR for the next 8-year period.The U.S. Market is Estimated at $222.2 Million, While China is Forecast to Grow at 13.6% CAGR
The Platelet Rich Plasma (PRP) market in the U.S. is estimated at US$222.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$379 Million by the year 2030 trailing a CAGR of 13.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 6.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.Select Competitors (Total 36 Featured) -
- AdiStem Ltd.
- Arthrex, Inc.
- Cesca Therapeutics, Inc.
- DePuy Synthes, Inc.
- Dr. PRP America, LLC
- EmCyte Corporation
- Exactech Inc.
- Glofinn Oy
- Harvest Technologies Corporation
- ISTO Biologics
- Nuo Therapeutics
- Stryker Corporation
- T-Biotechnology (T-LAB)
- Terumo BCT, Inc.
- Zimmer Biomet
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdiStem Ltd.
- Arthrex, Inc.
- Cesca Therapeutics, Inc.
- DePuy Synthes, Inc.
- Dr. PRP America, LLC
- EmCyte Corporation
- Exactech Inc.
- Glofinn Oy
- Harvest Technologies Corporation
- ISTO Biologics
- Nuo Therapeutics
- Stryker Corporation
- T-Biotechnology (T-LAB)
- Terumo BCT, Inc.
- Zimmer Biomet
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 92 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 815.6 Million |
Forecasted Market Value ( USD | $ 1600 Million |
Compound Annual Growth Rate | 8.8% |
Regions Covered | Global |